Paliperidone (Erzofri, Invega) — 2026 Medicare Part D coverage
paliperidone — sold as Erzofri, Invega: 24 forms appear in Medicare Part D formularies for 2026. This page reports what plans filed with CMS; it does not recommend a plan.
Which plans in your county cover paliperidone?
Pick a county to see every Medicare Advantage plan filed there and every stand-alone Part D plan in its region, with this drug's tier, restrictions and tier cost sharing.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.
Forms and strengths in 2026 formularies
| Form | Formularies listing it | Most common tier | PA | ST | QL |
|---|---|---|---|---|---|
| Invega Sustenna 117 MG in 0.75 mL Prefilled Syringe brand · RxCUI 858057 | 328 (100%) | 5 | 34 | 3 | 281 |
| Invega Sustenna 156 MG in 1 ML Prefilled Syringe brand · RxCUI 858055 | 328 (100%) | 5 | 34 | 3 | 281 |
| Invega Sustenna 234 MG in 1.5 ML Prefilled Syringe brand · RxCUI 858053 | 328 (100%) | 5 | 34 | 3 | 281 |
| Invega Sustenna 39 MG in 0.25 mL Prefilled Syringe brand · RxCUI 858074 | 328 (100%) | 4 | 34 | 3 | 279 |
| Invega Sustenna 78 MG in 0.5 mL Prefilled Syringe brand · RxCUI 858051 | 328 (100%) | 5 | 34 | 3 | 279 |
| paliperidone 1.5 MG 24HR Extended Release Oral Tablet generic · RxCUI 866103 | 328 (100%) | 4 | 58 | 5 | 306 |
| paliperidone 3 MG 24HR Extended Release Oral Tablet generic · RxCUI 672567 | 328 (100%) | 4 | 58 | 5 | 306 |
| paliperidone 6 MG 24HR Extended Release Oral Tablet generic · RxCUI 672569 | 328 (100%) | 4 | 58 | 5 | 308 |
| paliperidone 9 MG 24HR Extended Release Oral Tablet generic · RxCUI 672571 | 328 (100%) | 4 | 58 | 5 | 302 |
| Invega Hayfera 1092 MG in 3.5 ML Prefilled Syringe brand · RxCUI 2570419 | 299 (91%) | 5 | 21 | 19 | 257 |
| Invega Hayfera 1560 MG in 5 ML Prefilled Syringe brand · RxCUI 2570421 | 299 (91%) | 5 | 21 | 19 | 257 |
| Invega Trinza 273 MG in 0.88 ML Prefilled Syringe brand · RxCUI 1650968 | 297 (91%) | 5 | 19 | 1 | 253 |
| Invega Trinza 410 MG in 1.32 ML Prefilled Syringe brand · RxCUI 1650972 | 297 (91%) | 5 | 19 | 1 | 252 |
| Invega Trinza 546 MG in 1.75 ML Prefilled Syringe brand · RxCUI 1650974 | 297 (91%) | 5 | 19 | 1 | 252 |
| Invega Trinza 819 MG in 2.63 ML Prefilled Syringe brand · RxCUI 1650976 | 297 (91%) | 5 | 19 | 1 | 252 |
| Erzofri 117 MG in 0.75 ML Prefilled Syringe brand · RxCUI 2699350 | 150 (46%) | 5 | 21 | 2 | 141 |
| Erzofri 156 MG in 1 ML Prefilled Syringe brand · RxCUI 2699351 | 150 (46%) | 5 | 21 | 2 | 141 |
| Erzofri 234 MG in 1.5 ML Prefilled Syringe brand · RxCUI 2699352 | 150 (46%) | 5 | 21 | 2 | 141 |
| Erzofri 351 MG in 2.25 ML Prefilled Syringe brand · RxCUI 2699348 | 150 (46%) | 5 | 20 | 2 | 141 |
| Erzofri 78 MG in 0.5 ML Prefilled Syringe brand · RxCUI 2699354 | 150 (46%) | 5 | 21 | 2 | 141 |
| Erzofri 39 MG in 0.25 ML Prefilled Syringe brand · RxCUI 2699353 | 148 (45%) | 4 | 21 | 2 | 141 |
| INVEGA 3 MG 24HR Extended Release Oral Tablet brand · RxCUI 686441 | 1 (0%) | 1 | 1 | 0 | 1 |
| INVEGA 6 MG 24HR Extended Release Oral Tablet brand · RxCUI 686443 | 1 (0%) | 1 | 1 | 0 | 1 |
| INVEGA 9 MG 24HR Extended Release Oral Tablet brand · RxCUI 686445 | 1 (0%) | 1 | 1 | 0 | 1 |
Counts are formularies (of 328) in the CMS file that list the form, and how many of those apply prior authorization (PA), step therapy (ST) or a quantity limit (QL). Many plans share one formulary, so plan counts in a county will differ.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.